Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Global Market Report 2025

Description

Peptide therapeutics contract active pharmaceutical ingredient manufacturing involves outsourcing the production of peptide-based active pharmaceutical ingredients to specialized third-party manufacturers who operate under stringent regulatory standards. These manufacturers provide services such as custom synthesis, purification, and GMP-grade production to support both clinical trials and commercial supply of peptide therapeutics.

The primary scales of operation in peptide therapeutics contract API manufacturing include preclinical or clinical and commercial stages. The preclinical or clinical phase covers early drug development, involving laboratory research and human trials to assess the safety and effectiveness of peptide drugs. Various synthesis methods are employed, including both chemical and non-chemical approaches, catering to different types of enterprises, from large corporations to small and medium-sized businesses.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market research report is one of a series of new reports from The Business Research Company that provides peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market statistics, including the peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing industry's global market size, regional shares, competitors with the peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market share, detailed peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market. This peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market size has grown strongly in recent years. It will grow from $2.68 billion in 2024 to $2.89 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth during the historic period can be attributed to an expanding pipeline of peptide therapeutics, a rising global focus on personalized medicine, increased demand fueled by GLP-1 blockbuster drugs, heightened emphasis on sustainable manufacturing, and growing approval rates of peptide therapeutics.

The peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market size is expected to see strong growth in the next few years. It will grow to $3.84 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth anticipated in the forecast period is driven by the increasing prevalence of chronic diseases, rising demand for targeted biologic therapies, a growing preference for peptide-based therapeutics, expanded use of high-purity manufacturing, and increased investment in biotech research and development. Key trends during this period include advancements in solid-phase peptide synthesis, progress in liquid-phase peptide synthesis, the integration of hybrid synthesis methods, improvements in purification technologies, and the adoption of technology-driven continuous manufacturing processes.

The increasing prevalence of diabetes is expected to drive growth in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market moving forward. Diabetes is a chronic metabolic disorder characterized by elevated blood glucose levels caused by insufficient insulin production or the body's inability to use insulin effectively. This rise in diabetes cases is mainly driven by increasing obesity rates, as excess body fat contributes to insulin resistance and impairs blood sugar regulation. Peptide therapeutics utilize contract API manufacturing to support large-scale production of hormone-mimicking drugs that improve insulin secretion and glucose control in diabetes treatment. For example, in March 2025, the Office for Health Improvement and Disparities, a UK government department, reported that the prevalence of type 2 diabetes among adults aged 17 and older in England was 7.0% as of March 2024, up from 6.8% in March 2023. Hence, the growing prevalence of diabetes is fueling the peptide therapeutics contract API manufacturing market.

Key players in the peptide therapeutics contract API manufacturing market are focusing on innovative solutions like the continuous flow synthesis platform to enhance production speed and quality while managing increasing drug development complexity. This platform combines multiple stages-including reaction, separation, concentration, and crystallization-into a single, seamless process with real-time in-line monitoring, enabling precise, non-destructive control and efficient scale-up. For instance, in May 2023, SynCrest Inc., a Japan-based contract research, development, and manufacturing organization (CRDMO), launched its GMP-compliant Naruto Plant equipped with a continuous flow synthesis platform for producing peptide and nucleotide APIs. This technology facilitates rapid, high-quality manufacturing of over 100 types of non-natural amino acids and high-purity special amidites, substantially reducing lead times and costs. Such innovations meet growing demand for advanced peptide therapeutics by offering scalable, efficient, and cost-effective API manufacturing.

In December 2024, Novo Holdings A/S, a Denmark-based asset management firm, acquired Catalent Inc. for $16.5 billion. Through this acquisition, Novo Holdings aims to enhance the development and delivery of transformative therapies, improve patient outcomes worldwide, and create sustainable value in life sciences through active ownership. Catalent Inc., headquartered in the US, is a pharmaceutical company specializing in contract manufacturing services for active pharmaceutical ingredients, including peptide therapeutic APIs.

Major players in the peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market are Thermo Fisher Scientific Inc., Lonza Group AG., WuXi AppTec Co. Ltd., Cambrex Corporation, ChemPartner, GenScript Biotech Corporation, Bachem Group, CordenPharma International GmbH, Syngene International Limited, Ambiopharm Inc., CPC Scientific Inc., ScinoPharm Taiwan Ltd., Hybio Pharmaceutical Co. Ltd., CEM Corporation, CSBio Company Inc., Senn Chemicals AG., AnaSpec Inc., LifeTein LLC, Apex Biotechnology Corp., and BCN Peptides S.A.

North America was the largest region in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market includes revenues earned by entities through custom peptide synthesis, process development and optimization, and analytical development and quality control. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Scale Of Operation: Preclinical Or Clinical; Commercial
2) By Synthesis Method: Non Chemical Synthesis; Chemical Synthesis
3) By Enterprise Type: Large Enterprise; Small And Medium Enterprises
Subsegments:
1) By Preclinical Or Clinical: Discovery And Preclinical Development; Phase II Or III Manufacturing; Phase I Manufacturing
2) By Commercial: Commercial-Scale Good Manufacturing Practice Manufacturing; Tech Transfer And Scale-up; Lifecycle Management Or Process Optimization
Companies Mentioned: Thermo Fisher Scientific Inc.; Lonza Group AG.; WuXi AppTec Co. Ltd.; Cambrex Corporation; ChemPartner; GenScript Biotech Corporation; Bachem Group; CordenPharma International GmbH; Syngene International Limited; Ambiopharm Inc.; CPC Scientific Inc.; ScinoPharm Taiwan Ltd.; Hybio Pharmaceutical Co. Ltd.; CEM Corporation; CSBio Company Inc.; Senn Chemicals AG.; AnaSpec Inc.; LifeTein LLC; Apex Biotechnology Corp.; BCN Peptides S.A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r37099

1. Executive Summary

2. Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Characteristics

3. Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Trends And Strategies

4. Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Growth Analysis And Strategic Analysis Framework

5.1. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Growth Rate Analysis
5.4. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Total Addressable Market (TAM)

6. Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Segmentation

6.1. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Preclinical Or Clinical
Commercial
6.2. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Non Chemical Synthesis
Chemical Synthesis
6.3. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Large Enterprise
Small And Medium Enterprises
6.4. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Sub-Segmentation Of Preclinical Or Clinical, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Discovery And Preclinical Development
Phase II Or III Manufacturing
Phase I Manufacturing
6.5. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Sub-Segmentation Of Commercial, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Commercial-Scale Good Manufacturing Practice Manufacturing
Tech Transfer And Scale-up
Lifecycle Management Or Process Optimization

7. Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Regional And Country Analysis

7.1. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

8.1. Asia-Pacific Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

9.1. China Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview
9.2. China Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

10.1. India Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

11.1. Japan Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview
11.2. Japan Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

12.1. Australia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

13.1. Indonesia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

14.1. South Korea Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview
14.2. South Korea Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

15.1. Western Europe Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview
15.2. Western Europe Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

16.1. UK Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

17.1. Germany Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

18.1. France Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

19.1. Italy Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

20.1. Spain Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

21.1. Eastern Europe Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview
21.2. Eastern Europe Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

22.1. Russia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

23.1. North America Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview
23.2. North America Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

24.1. USA Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview
24.2. USA Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

25.1. Canada Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview
25.2. Canada Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

26.1. South America Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview
26.2. South America Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

27.1. Brazil Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

28.1. Middle East Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview
28.2. Middle East Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

29.1. Africa Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview
29.2. Africa Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Competitive Landscape And Company Profiles

30.1. Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Competitive Landscape
30.2. Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Company Profiles
- 30.2.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Lonza Group AG. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. WuXi AppTec Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Cambrex Corporation Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. ChemPartner Overview, Products and Services, Strategy and Financial Analysis

31. Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Other Major And Innovative Companies

31.1. GenScript Biotech Corporation
31.2. Bachem Group
31.3. CordenPharma International GmbH
31.4. Syngene International Limited
31.5. Ambiopharm Inc.
31.6. CPC Scientific Inc.
31.7. ScinoPharm Taiwan Ltd.
31.8. Hybio Pharmaceutical Co. Ltd.
31.9. CEM Corporation
31.10. CSBio Company Inc.
31.11. Senn Chemicals AG.
31.12. AnaSpec Inc.
31.13. LifeTein LLC
31.14. Apex Biotechnology Corp.
31.15. BCN Peptides S.A.

32. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

34. Recent Developments In The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

35. Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market High Potential Countries, Segments and Strategies

35.1 Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market In 2029 - Countries Offering Most New Opportunities
35.2 Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market In 2029 - Segments Offering Most New Opportunities
35.3 Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer